Pfitzner BM, Lederer B, Lindner J, Solbach C, Engels K, et al. Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years. Mod Pathol. 2017 Dec 22. [Epub ahead of print].
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2017 Dec 11. [Epub ahead of print].
Han SN, Amant F, Cardonick EH, Loibl S, Peccatori FA, et al. Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Res Treat. 2017 Dec 12. [Epub ahead of print].
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017 Dec 7 [Epub ahead of print].
Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, et al. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2017 Nov 25 [Epub ahead of print].
Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Nov 17 [Epub ahead of print].
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836-1846.
Schirm S, Engel C, Loibl S, Loeffler M, Scholz M. Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. J Cancer Res Clin Oncol. 2017; [Epub ahead of print].
Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, et al. A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer. Ann Oncol. 2017; [Epub ahead of print].
Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017; 551:92-94.
Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49:1767-1778.
Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Eur J Cancer. 2017;85:133-145.
van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2017 Sep 5. [Epub ahead of print].
van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, et al. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. Breast Cancer Res Treat. 2017; 166:775-785.
Kümmel S, Paepke S, Huober J, Schem C, Untch M, et al. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Eur J Cancer. 2017;84:1-8.
Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017; 3:1378-1385.
Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, et al. The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. NPJ Breast Cancer. 2017;3:23.
Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, et al. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res. 2017;23:5384-5393.
Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, et al. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist. 2017; 22:1028-1038.
Möbus V, von Minckwitz G, Jackisch C, Lück HJ, Schneeweiss A, et al. A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients. Ann Oncol. 2017; 28:1803-1810.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017; 377:122-131.
Reimer T, Stachs A, Nekljudova V, Loibl S, Hartmann S, et al. Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd. 2017;77:149-157.
Furlanetto J, Jackisch Ch, Untch M, Schneeweiss A, Schmatloch S, et al. Efficacy and safety of nab-paclitaxel 125 mg/m2 and nabpaclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Res Treat. 2017;163(3): 495-506.
Reinisch M, Huober J, von Minckwitz G, Blohmer JU, Denkert C, et al. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials. Breast. 2017;32:73-78.
Mamounas EP, Kuehn T, Rutgers EJT, von Minckwitz G. Current approach of the axilla in patients with early-stage breast cancer. Lancet 2017 Aug 14. [Epub ahead of print].
Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389:2430-2442.
Hendry S, Salgado R, Gevaert T, Russell PA, John T, et al. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017;24:235-251.
Hendry S, Salgado R, Gevaert T, Russell PA, John T, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017;24:235-251.
Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017;Ann Oncol. 2017; 28:1700-1712.